Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14314075 | 0.86 | RXRA (0.50) | RXRARXRBRAB9ANPC1KDM4E | |
| SCHEMBL19387288 | 0.84 | RXRA (0.49) | RXRARXRBRAB9ANPC1KDM4E | |
| SCHEMBL5486063 | 0.81 | LMNA (0.50) | RAB9ANPC1KDM4EL3MBTL1SMN1; SMN2 | |
| SCHEMBL25063894 | 0.81 | MEN1 (0.52) | RXRARXRBRAB9ANPC1KDM4E | |
| SCHEMBL15426513 | 0.81 | PRKCA (0.47) | RXRARXRBRAB9ANPC1KDM4E | |
| SCHEMBL16452391 | 0.79 | SMN1; SMN2 (0.56) | RXRARXRBRAB9ANPC1POLB | |
| SCHEMBL18211356 | 0.77 | ELANE (0.66) | RXRARXRBRAB9ANPC1KDM4E | |
| SCHEMBL10165860 | 0.76 | RAB9A (0.58) | RXRARXRBRAB9ANPC1KDM4E | |
| SCHEMBL2129283 | 0.75 | KMT2A (0.46) | RXRARXRBRAB9ANPC1KDM4E | |
| SCHEMBL4456474 | 0.74 | IDO1 (0.55) | RXRARXRBRAB9ANPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9254339-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150306240-A1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-10-29 | — | — | US | disclosed |
| US-9144615-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8821850-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815226-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8808679-B2 | Auristatin compounds and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | MERSANA THERAPEUTICS, INC. (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150044160-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | RXRA 1721/4885RXRB 1708/4885RAB9A 1447/4885 |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | RXRA 1721/4885RXRB 1708/4885RAB9A 1447/4885 |
| US-20140134127-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | RXRA 1721/4885RXRB 1708/4885RAB9A 1447/4885 |
| US-20160022829-A1 | TUBULYSIN COMPOUNDS AND CONJUGATES THEREOF | LGMN, TLL1, TEK | RXRA 2854/4885RXRB 2525/4885RAB9A 3137/4885 |
| US-20160067353-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | RXRA 1721/4885RXRB 1708/4885RAB9A 1447/4885 |
| US-20150306240-A1 | HYDROXYL-POLYMER-DRUG-PROTEIN CONJUGATES | PBRM1, HDGFL3, CLTB | RXRA 2156/4885RXRB 2130/4885RAB9A 1955/4885 |
| US-20120321583-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | RXRA 1721/4885RXRB 1708/4885RAB9A 1447/4885 |
| US-20150064130-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, PEBP1, STAMBP | RXRA 2262/4885RXRB 2035/4885RAB9A 2172/4885 |
| US-20150314008-A1 | AURISTATIN COMPOUNDS AND CONJUGATES THEREOF | PBRM1, BRWD1, BRDT | RXRA 2696/4885RXRB 2307/4885RAB9A 2500/4885 |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MALT1, ALG1, PRMT3 | RXRA 1757/4885RXRB 2285/4885RAB9A 3040/4885 |
| US-20130101546-A1 | Protein-Polymer-Drug Conjugates | PBRM1, CLTB, BRAP | RXRA 1694/4885RXRB 1729/4885RAB9A 1453/4885 |
| US-20130309192-A1 | Auristatin Compounds and Conjugates Thereof | PBRM1, AURKB, PEBP1 | RXRA 2222/4885RXRB 1812/4885RAB9A 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.